

Mumbai, 31st August, 2020

Wockhardt Announces the Appointment of Mr. Akhilesh Gupta on the Board

Wockhardt appointed Mr. Akhilesh Gupta as an Additional Director (Non-Executive, Independent) w.e.f. August 29th, 2020.

He was the Chairman of Blackstone India till December 2014. He joined The Blackstone Group as Senior Managing Director in 2005 and started its operations in India. Before joining Blackstone, Mr. Gupta served as CEO - Corporate Development for Reliance Industries Limited.

Mr. Gupta began his career at Hindustan Unilever and also worked in the US, first in consulting with Strategic Planning Associates and ICF International in Washington D.C., where he became a partner at the firm and then as Chief Financial Officer of two integrated retailers and manufacturers of furniture in California.

Dr. Habil Khorakiwala, Founder Chairman on his joining the Board of Directors said “Wockhardt has always been enriched with its’ diverse and illustrious Board and Akhilesh’s joining would further strengthen it. His enriching experience of running global organisations will further augment the Board.”

Mr. Gupta, an MBA from the Graduate School of Business, Stanford University in 1981 and B.Tech in Chemical Engineering from the Indian Institute of Technology, Delhi (IIT, Delhi) has served over a dozen company Boards, including Boards of several Blackstone portfolio companies, Larsen & Toubro,

and Reliance group companies. IIT, Delhi conferred on him the Distinguished Alumni Award in 2004.

Mr. Gupta currently serves on the Advisory Council of the Graduate School of Business at Stanford University, on The Dean's Leadership Council at Harvard Divinity School, on the Advisory Board of Human Flourishing Initiative at Harvard University and on the Board of World Teach. He is one of the founding members of Asia Society (India Chapter) and a Partner in The Acumen Fund.

About Wockhardt:

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Diseases Programme) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt is employing over 5000 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 82% of its global revenues coming from international businesses.